PT145 Primary Utilization of EECP In Chronic Stable Angina Patients With Left Ventricular Dysfunction and Long Time Follow Up

Gandhi, Pratiksha G; Subramanian, Raghavan; Mittal, Monica

doi:10.1016/j.gheart.2014.03.1921

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Exclusion of any single study did not remarkable alter the overall pooled proportion, with a range from 84% (95%CI 0.81–0.87, I 2 = 30.6%) to 86% (95%CI 0.82–0.89, I 2 = 56.5%) (Fig. 3 ).We excluded 3 large studies 20 , 21 , 36 to compute the overall pooled proportion with a fixed effect model, the pooled proportion was 82% (95%CI 0.79–0.86, I 2 = 18%, P = 0.2528) (Fig. 4 ).…”

Section: Resultsmentioning

confidence: 95%

“…The later study suggested that 50% had an improvement in the quality-of-life post-EECP that was also lasted at 2 years. Besides the prior publication 36 that the patients were followed up for 3.5 years indicated that about 66.4% sustained EECP treatment benefit. Even so, further studies were warranted to assess the long-term effects of EECP therapy.…”

Section: Discussionmentioning

confidence: 96%

See 1 more Smart Citation

Efficacy of Enhanced External Counterpulsation in Patients With Chronic Refractory Angina on Canadian Cardiovascular Society (CCS) Angina Class

et al. 2015

View full text Add to dashboard Cite

A growing number of patients with chronic artery disease suffer from angina, despite the optimal medical management (ie, β-blockers, calcium channel blockers, and long-acting nitrates) and revascularization. Currently, enhanced external counterpulsation (EECP) therapy has been verified as a noninvasive, safe therapy for refractory angina. The study was designed to evaluate the efficacy of EECP in patients with chronic refractory angina according to Canadian Cardiovascular Society (CCS) angina class.We identified systematic literature through MEDLINE, EMBASE, the Cochrane Clinical Trials Register Database, and the ClinicalTrials. gov Website from 1990 to 2015. Studies were considered eligible if they were prospective and reported data on CCS class before and after EECP treatment. Meta-analysis was performed to assess the efficacy of EECP therapy by at least 1 CCS angina class improvement, and proportion along with the 95% confidence interval (CI) was calculated. Statistical heterogeneity was calculated by I2 statistic and the Q statistic. Sensitivity analysis was addressed to test the influence of trials on the overall pooled results. Subgroup analysis was applied to explore potential reasons for heterogeneity.Eighteen studies were enrolled in our meta-analysis. Pooled analysis showed 85% of patients underwent EECP had a reduction by at least one CCS class (95%CI 0.81–0.88, I2 = 58.5%, P < 0.001). The proportion of patients enrolled at primarily different studies with chronic heart failure (CHF) improved by at least 1 CCS class was about 84% after EECP (95%CI 0.81–0.88, I2 = 32.7%, P = 0.1668). After 3 large studies were excluded, the pooled proportion was 82% (95%CI 0.79–0.86, I2 = 18%, P = 0.2528). Funnel plot indicated that some asymmetry while the Begg and Egger bias statistic showed no publication bias (P = 0.1495 and 0.2859, respectively).Our study confirmed that EECP provided an effective treatment for patients who were unresponsive to medical management and/or invasive therapy. However, the long-term benefits of EECP therapy needed further studies to evaluate in the management of chronic refractory angina.

show abstract

Section: Resultsmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 96%